About
Dr. Timothy Budden is a Lecturer in the Department of Molecular and Clinical Cancer Medicine at the University of Liverpool.
He completed his PhD at the University of Newcastle in Australia in 2017, where he studied melanoma and DNA damage repair, investigating how ultraviolet radiation (UV) and chemotherapies affect both melanoma development and resistance to treatment. Following this, he held a postdoctoral position at the University of New South Wales in Sydney, where he conducted tumour profiling of ovarian cancers to identify prognostic biomarkers and genetic risk factors.
In 2018 he moved to Manchester UK, where his postdoctoral work at the Cancer Research UK Manchester Institute further expanded his expertise in skin cancer and melanoma. He studied how chronic UV damage alters fibroblast behaviour within the tumour microenvironment and alter primary melanoma progression, He also uncovered the molecular mechanisms behind sex bias in skin cancer, explaining why men are more prone to developing skin cancers than women.
Currently, his research explores fibroblast metabolic diversity across different tissue types, examining how these variations influence epithelial cancers, including their development and clinical outcomes. He also investigates how chronic exposure to environmental carcinogens such as UV radiation, tobacco, and alcohol leads to tissue-specific extrinsic ageing, affecting both fibroblast biology and the onset of epithelial cancers. His work emphasizes the early stages of disease, aiming to uncover novel pathways and biomarkers for cancer prevention and early intervention.
Prizes or Honours
- Chris Marshall Prize for Cell Signalling 2022 (British Association for Cancer Research, 2022)
- Edith Paterson Prize Best Young Scientist 2021 (Cancer Research UK Manchester Institute, 2021)